Literature DB >> 9459451

Glutamate receptor GluR3 antibodies and death of cortical cells.

X P He1, M Patel, K D Whitney, S Janumpalli, A Tenner, J O McNamara.   

Abstract

Rasmussen's encephalitis (RE), a childhood disease characterized by epileptic seizures associated with progressive destruction of a single cerebral hemisphere, is an autoimmune disease in which one of the autoantigens is a glutamate receptor, GluR3. The improvement of some affected children following plasma exchange that removed circulating GluR3 antibodies (anti-GluR3) suggested that anti-GluR3 gained access to the central nervous system where it exerted deleterious effects. Here, we demonstrate that a subset of rabbits immunized with a GluR3 fusion protein develops a neurological disorder mimicking RE. Anti-GluR3 IgG isolated from serum of both ill and healthy GluR3-immunized animals promoted death of cultured cortical cells by a complement-dependent mechanism. IgG immunoreactivity decorated neurons and their processes in neocortex and hippocampus in ill but not in healthy rabbits. Moreover, both IgG and complement membrane attack complex (MAC) immunoreactivity was evident on neurons and their processes in the cortex of a subset of patients with RE. We suggest that access of IgG to epitopes in the central nervous system triggers complement-mediated neuronal damage and contributes to the pathogenesis of both this animal model and RE.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9459451     DOI: 10.1016/s0896-6273(00)80443-2

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  18 in total

1.  Autoantibodies against an extracellular peptide of the GluR3 subtype of AMPA receptors activate both homomeric and heteromeric AMPA receptor channels.

Authors:  Katayun Cohen-Kashi Malina; Yonatan Ganor; Mia Levite; Vivian I Teichberg
Journal:  Neurochem Res       Date:  2006-09-12       Impact factor: 3.996

2.  In Rasmussen encephalitis, hemichannels associated with microglial activation are linked to cortical pyramidal neuron coupling: a possible mechanism for cellular hyperexcitability.

Authors:  Carlos Cepeda; Julia W Chang; Geoffrey C Owens; My N Huynh; Jane Y Chen; Conny Tran; Harry V Vinters; Michael S Levine; Gary W Mathern
Journal:  CNS Neurosci Ther       Date:  2014-12-01       Impact factor: 5.243

Review 3.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 4.  [Recent insights into Rasmussen encephalitis].

Authors:  C G Bien; C E Elger
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

5.  Glutamate enhances the surface distribution and release of Munc18 in cerebral cortical neurons.

Authors:  Ping Wan; Yan-Ping Zhang; Jie Yan; Yu-Xia Xu; Hong-Quan Wang; Ru Yang; Cui-Qing Zhu
Journal:  Neurosci Bull       Date:  2010-08       Impact factor: 5.203

Review 6.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

7.  Neutral antibodies to the TSH receptor are present in Graves' disease and regulate selective signaling cascades.

Authors:  Syed A Morshed; Takao Ando; Rauf Latif; Terry F Davies
Journal:  Endocrinology       Date:  2010-09-15       Impact factor: 4.736

8.  GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins.

Authors:  K D Whitney; J O McNamara
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

Review 9.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

Review 10.  Diagnostic and pathogenic significance of glutamate receptor autoantibodies.

Authors:  David Pleasure
Journal:  Arch Neurol       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.